-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：可口可乐(KO)公布的第一季度调整后每股收益为0.86美元，高于预期的0.73美元（增长18%），远超市场普遍预期的0.81美元。业绩超预期主要得益于营收增长强劲，净销售额增长12%至124.7亿美元（超出市场预期2.4亿美元），毛利率上升40个基点至63.0%（符合预期）。从可口可乐第一季度净销售额的增长来看，主要归功于浓缩液销售增长（+8%）、价格/产品组合优化（+2%）以及汇率波动（+3%）。鉴于可口可乐在美国以外的市场占有相当大的份额（预计2025年将占其总收入的约60%），近期美元走软已成为其业绩增长的关键利好因素。单箱销量增长3%，所有地区的销量均有所增长。可口可乐 (KO) 目前预计全年调整后每股收益将增长 8%-9%，高于此前预期的 7%-8%，并预计 2025 年每股收益将达到 3.00 美元，这意味着每股收益将达到 3.24-3.27 美元，高于目前市场普遍预期的 3.23 美元。可口可乐股价在盘前交易中上涨了 3%。我们认为，可口可乐整体销量增长最为令人鼓舞，这有助于缓解市场对注重性价比的消费者可能抵制该股的担忧。
Related Articles
Sectors
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
$PCAR
Australia
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%
$ERAS